Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Top Cited Papers
Open Access
- 3 December 2020
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (3), 312-320
- https://doi.org/10.1136/annrheumdis-2020-218870
Abstract
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). Methods In this 24-week randomised, placebo-controlled, double-blind, phase 3 trial, 642 patients were randomised (2:2:1:1) to once per day upadacitinib 15 mg or 30 mg, placebo followed by upadacitinib 15 mg or placebo followed by upadacitinib 30 mg at week 24. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 12. Achievement of minimal disease activity (MDA) was assessed at week 24. Treatment-emergent adverse events are reported for all patients who received at least one dose of trial drug. Results At week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg versus placebo achieved ACR20 (56.9% and 63.8% vs 24.1%; pConclusion In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of PsA. Clinical trial registration number NCT03104374Keywords
Funding Information
- AbbVie
This publication has 29 references indexed in Scilit:
- Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic ArthritisArthritis & Rheumatology, 2016
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisThe New England Journal of Medicine, 2015
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trialsJournal of Dermatological Treatment, 2013
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 2013
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals Of The Rheumatic Diseases, 2009
- Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis IndexAnnals Of The Rheumatic Diseases, 2008
- Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritisArthritis Care & Research, 2008
- Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritisAnnals Of The Rheumatic Diseases, 2007
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978